Last reviewed · How we verify
Minocycline Hydrochloride (MINOCYCLINE)
MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death.
Minocycline Hydrochloride, also known as MINOCYCLINE, is a tetracycline-class antibiotic developed by TRIAX PHARMS and currently owned by Rempex. It is a small molecule modality that has been FDA-approved since 1971 for various indications, including acne, infections, and anthrax. MINOCYCLINE is available as a generic medication, with 23 generic manufacturers, and is off-patent. It has a high bioavailability of 97% and a half-life of 17.0 hours. MINOCYCLINE is used to treat a range of bacterial infections.
At a glance
| Generic name | MINOCYCLINE |
|---|---|
| Sponsor | Rempex |
| Drug class | Tetracycline-class Drug |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1971 |
Mechanism of action
mechanism of action. The tetracyclines are primarily bacteriostatic and are thought to exert their antimicrobial effect by the inhibition of protein synthesis. The tetracyclines, including minocycline, have similar antimicrobial spectrum of activity against wide range of gram-positive and gram-negative organisms. Cross-resistance of these organisms to tetracycline is common.
Approved indications
- Acne vulgaris
- Actinomycotic infection
- Acute gonococcal cervicitis
- Acute gonococcal endometritis
- Acute gonococcal urethritis
- Anthrax
- Bartonellosis
- Bronchitis
- Brucellosis
- Chancroid
- Chlamydia trachomatis infection of genital structure
- Cholera
- Fusospirochetal pharyngitis
- Gingivostomatitis
- Gonorrhea
- Gonorrhea of pharynx
- Gonorrhea of rectum
- Granuloma inguinale
- Inclusion conjunctivitis
- Infection by Campylobacter fetus
Common side effects
- Hepatitis
- Liver failure
- Pancreatitis
- Pseudomembranous colitis
- Enterocolitis
- Esophagitis
- Esophageal ulcerations
- Vulvovaginitis
- Hyperbilirubinemia
- Hepatic cholestasis
- Increases in liver enzymes
- Fever
Drug interactions
- warfarin
- zinc sulfate
Key clinical trials
- Minocycline as Adjunctive Treatment for Treatment Resistant Depression (PHASE3)
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Minocycline in Stroke Study at Maimonides (PHASE2,PHASE3)
- Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment (NA)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Topical Minocycline for CARP (EARLY_PHASE1)
- Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke (PHASE2)
- Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minocycline Hydrochloride CI brief — competitive landscape report
- Minocycline Hydrochloride updates RSS · CI watch RSS
- Rempex portfolio CI